Jefferies downgraded Verona Pharma (VRNA) to Hold from Buy with a price target of $107, down from $140, after the company entered into an agreement under which Merck (MRK) will acquire it for $107 per American depository share, or $10B. Jefferies sees no regulatory risks for the deal.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Video: Verona Pharma jumps after agreeing to be acquired by Merck for $10B
- Morning Movers: Starbucks climbs following reports of interest in China business
- Verona Pharma Stock (VRNA) Soars 20% on $10B Merck Deal
- Verona Pharma Acquired by Merck for $10 Billion
- Merck to acquire Verona Pharma for $107.00 per ADS